Stiolto Respimat
Payments companies reported to CMS as associated with Stiolto Respimat. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Stiolto Respimat, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Stiolto Respimat
These are the largest totals companies reported as associated with Stiolto Respimat. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Douglas Hogarth | Chicago, IL | Pulmonary Disease | $17,391.01 |
| Stephen Brunton | Winnsboro, SC | Family Medicine | $13,682.76 |
| Michael Drummond | Baltimore, MD | Pulmonary Disease | $10,344.38 |
| John Oppenheimer | Cedar Knolls, NJ | Allergy | $9,626.04 |
| Michael Wechsler | Denver, CO | Pulmonary Disease | $9,452.25 |
| Antonio Anzueto | San Antonio, TX | Pulmonary Disease | $9,222.95 |
| Ashley Henderson | Chapel Hill, NC | Pulmonary Disease | $6,768.82 |
| Surya Bhatt | Bethlehem, PA | Pulmonary Disease | $6,250.00 |
| Sanjay Sethi | Buffalo, NY | Internal Medicine | $5,322.79 |
| Yuh Chin Huang | Durham, NC | Critical Care Medicine (Internal Medicine) | $4,192.50 |
Prescribed Stiolto Respimat?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.